We’ve all heard about the wonders of glucosamine. In fact, it’s become one of those old-school standbys, falling by the wayside in favor of newer, more exciting supplements.
But hold on to your hats… because new research has discovered an entirely different use for glucosamine that might just give this joint care dinosaur a second shot at stardom.
Double duty heart protection
According to a new report from a team of U.K. researchers, people who take glucosamine supplements regularly also appear to have a lower risk of events related to cardiovascular disease.
Specifically, taking glucosamine:
- Lowered risk of total heart disease events by 15 percent
- Lowered risk of stroke, coronary heart disease (CHD), and heart disease death by as much as 22 percent
This is news, even to me! And while detractors might say 15 percent isn’t all that great of an effect, I must point out it is significant. In fact, not only were results consistent, they were also similar to just about every other protective dietary factor in the book.
Believe it or not, this isn’t even the first time research has demonstrated as much. There are a few other studies—like the Vitamins and Lifestyle (VITAL) study—that showed using glucosamine at least four days a week for three years can lower total mortality risk by as much as 17 percent.
So I think we can all agree that’s pretty amazing. But I, for one, want to know why no one is talking about it.
These researchers point to animal studies suggesting that glucosamine’s anti-inflammatory properties may be driving this benefit—or that it may even mimic the metabolic benefits of a low-carb diet.
(Yes, you read that right. They actually admitted that low carb diets are cardioprotective. But as usual, they ended up hiding it in a throwaway sentence.)
I’ll refrain from too much head-shaking, though. Because at the end of the day, it’s nice to see any research throwing supplements a bone—instead of under the bus.
Negativity from the naysayers
Interestingly, while results linked glucosamine use with significantly lower risk of fatal and non-fatal CHD, there was hardly any influence on risk of fatal or non-fatal stroke.
This could be because CHD is a macrovascular disease—that is, one that affects the larger blood vessels—whereas stroke is microvascular. But time will tell how that shakes out.
In the meantime, let’s have some fun contending with the naysayers…
A lot of them are saying they wouldn’t recommend taking glucosamine for heart health. At least, not until there’s a multi-million-dollar trial to confirm these results.
They also point out that the study didn’t include information on the dosage or duration of glucosamine supplementation. Or on its side effects—which would be a fair complaint, if glucosamine wasn’t already well established as one of the safest arthritis supplements on the market.
This is your scientific community at work, folks. Because you can bet your very last dollar that if a pharmaceutical drug had demonstrated this same effect, it would receive billions in funding… and get fast tracked to market quicker than you could read this sentence.
Let’s not forget, these are the same people that try to force-feed you statins. And on far less compelling evidence, I might add.
Glucosamine is safe and effective, with the track record to prove it. So if you’re already taking it for arthritis relief, by all means, keep doing so. And if you aren’t? Well, it looks like now you have a pretty good reason to start. I recommend 250 mg of N-acetyl glucosamine twice daily from a high-quality supplement, which you should be able to find at your local vitamin shop.
P.S. For more all-natural ways to prevent and reverse America’s biggest killers—high blood pressure, heart attack, and stroke—I encourage you to check out my Ultimate Heart-Protection Protocol. Because you don’t have to die from a heart attack or stroke… and you certainly don’t need to take dangerous, side-effect-laden drugs. Click here to learn more about this innovative online learning tool today!
“Glucosamine Supplements Linked to Lower CVD Event Risks.” Medscape Medical News, 05/14/2019. (medscape.com/viewarticle/913016)